The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices announced its support of a new vaccine aimed at keeping young people safe from meningococcal disease.
Manufactured by Pfizer, Penbraya is an immunization designed to block life-threatening infections caused by the bacteria Neisseria meningitidis serogroups A, B, C, W, and Y, responsible for most meningococcal disease in teens and young adults ages 16 to 23 years old. The bacteria are spread through close personal contact, like living together or kissing.
